Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04556123
Other study ID # 2074/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 13, 2020
Est. completion date April 1, 2023

Study information

Verified date July 2023
Source Medical University of Vienna
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fluid overload (FO) puts aortic stenosis (AS) patients at risk for heart failure and death. However, conventional FO assessment, including rapid weight gain, peripheral edema, or chest radiography, is inaccurate. Bioelectrical impedance spectroscopy (BIS) allows objective and reproducible FO quantification, particularly if clinically unapparent. FO as detected with BIS has recently been linked to worse clinical outcomes of AS patients undergoing transcatheter aortic valve replacement (TAVR). It is the aim of the present randomised trial to evaluate the potential clinical benefit of pursuing an individualized decongestion treatment strategy in consecutive TAVR patients using BIS.


Description:

This study is a randomized controlled trial investigating the effect of BIS-guided decongestive treatment on clinical outcomes in overhydrated patients scheduled for and receiving TAVR. Centers participating in this trial are: Medical University of Vienna, Kepler University Hospital Linz Consecutive adult patients with severe degenerative AS scheduled for TAVR will be prospectively enrolled at university-affiliated tertiary centers in Austria. Eligibility and decision for TAVR will be determined by a multidisciplinary Heart Team. All patients who are willing to participate will undergo assessment of volume status using BIS prior to intervention. Overhydrated subjects, defined as a relative fluid overload ≥7% (Rel. FO = fluid overload/extracellular water × 100%) and/or absolute fluid overload ≥1L as assessed by BIS, will then be randomly assigned to undergo BIS-guided pre- and postprocedural decongestion treatment vs. decongestion treatment based on mere clinical judgement of volume status in a 1:1 fashion. In order to avoid detection bias, FO patients in the non-BIS group as well as their treating physicians shall be blinded for BIS-results. Physicians and study participants will only be informed about the targeted dry body weight, if randomized to the BIS-guided decongestion group. Decongestion will be performed using standard medication (e.g. loop diuretics) and applied orally or intravenously, as appropriate. After TAVR, patients with FO will be followed before discharge from the hospital, after 3, 6 and 12 months. Methods: Patients will undergo standardized evaluation of their fluid status using a portable whole-body BIS device, the Body Composition Monitor (BCM, Fresenius Medical Care, Bad Homburg, Germany). Patients will be placed in supine position before the evaluation of their fluid status. Electrodes will be attached to the nondominant hand and the ipsilateral foot. Measurements will be conducted according to the manufacturer's manual. For each patient, only one bioelectrical impedance analysis will be performed, as this method has an adequate reproducibility. Fluid overload assessed by BCM is expressed as an absolute value in liters or as a relative value in %, calculated as the ratio between fluid overload (FO) and the content of extracellular water (ECW) and multiplied by 100 (Rel. FO = FO/ECW × 100%). Prespecified study visits: V0 (14+-13 days prior to TAVR): BIS measurement, pitting edema quantification, demographic factors, symptom assessment, cardiovascular risk factors, ECG, laboratory analysis (e.g. NT-pro BNP, hs-TnT), frailty assessment, KCCQ questionnaire, transthoracic echocardiography; V1 (90+-7 days post TAVR): BIS measurement, pitting edema quantification, demographic factors, symptom assessment, ECG, laboratory analysis (e.g. NT-pro BNP, hs-TnT), KCCQ questionnaire, transthoracic echocardiography; TV2 (telephone visit, 180+-7 days post TAVR): demographic factors, symptom assessment; V3 (360+-7 days post TAVR, =end of treatment): BIS measurement, pitting edema quantification, demographic factors, symptom assessment, ECG, laboratory analysis (e.g. NT-pro BNP, hs-TnT), KCCQ questionnaire, transthoracic echocardiography; Outcome: Cardiac outcomes (see below) will be assessed at 3 months (=prespecified interim analysis), and 12 months follwing TAVR.


Recruitment information / eligibility

Status Completed
Enrollment 232
Est. completion date April 1, 2023
Est. primary completion date April 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent - Age =18 years - Scheduled TAVR for the treatment of severe aortic stenosis - Fluid overlaod =7% and/or =1L by BIS prior to TAVR (necessary to undergo randomization process) Exclusion Criteria: - Unwillingness or inability to participate - Pregnancy - Chronic dialysis - Severe electrolyte disorders

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Measurement of the hydration state and decongestive treatment according to bioimpedance spectroscopy
The measurements will be performed in each center by a reference physician or nurse, using a portable whole body bioimpedance spectroscopy device, BCM (Fresenius Medical Care). The electrodes will be attached to one hand and one foot on the ipsilateral side, after the patient has been in the supine position for at least 5 minutes.
Measurement of the hydration state and decongestive treatment according to clinical judgement alone
Clinical judgement will be performed in each center by a reference physician or nurse

Locations

Country Name City State
Austria Karl Landsteiner University St.Pölten Niederösterreich
Austria Medical University of Vienna Vienna

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

References & Publications (8)

Hong YA, Yoon HE, Choi BS, Shin SJ, Kim YS, Lee SY, Lee SH, Kim SH, Lee EY, Shin SK, Kwon YJ, Kim JH, Chang YK, Kim SY, Kim JE, Ahn SY, Ko GJ. The Effect of Strict Volume Control Assessed by Repeated Bioimpedance Spectroscopy on Cardiac Function in Peritoneal Dialysis Patients. Sci Rep. 2019 Nov 27;9(1):17679. doi: 10.1038/s41598-019-53792-0. — View Citation

Hur E, Usta M, Toz H, Asci G, Wabel P, Kahvecioglu S, Kayikcioglu M, Demirci MS, Ozkahya M, Duman S, Ok E. Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial. Am J Kidney Dis. 2013 Jun;61(6):957-65. doi: 10.1053/j.ajkd.2012.12.017. Epub 2013 Feb 15. — View Citation

Koell B, Zotter-Tufaro C, Duca F, Kammerlander AA, Aschauer S, Dalos D, Antlanger M, Hecking M, Saemann M, Mascherbauer J, Bonderman D. Fluid status and outcome in patients with heart failure and preserved ejection fraction. Int J Cardiol. 2017 Mar 1;230:476-481. doi: 10.1016/j.ijcard.2016.12.080. Epub 2016 Dec 21. — View Citation

Machek P, Jirka T, Moissl U, Chamney P, Wabel P. Guided optimization of fluid status in haemodialysis patients. Nephrol Dial Transplant. 2010 Feb;25(2):538-44. doi: 10.1093/ndt/gfp487. Epub 2009 Sep 30. — View Citation

Mulasi U, Kuchnia AJ, Cole AJ, Earthman CP. Bioimpedance at the bedside: current applications, limitations, and opportunities. Nutr Clin Pract. 2015 Apr;30(2):180-93. doi: 10.1177/0884533614568155. Epub 2015 Jan 22. Erratum In: Nutr Clin Pract. 2015 Aug;30(4):589. — View Citation

Nitsche C, Kammerlander AA, Koschutnik M, Dona C, Aschauer S, Sinnhuber L, Eidenberger A, Forutan N, Schartmueller F, Andreas M, Beitzke D, Bergler-Klein J, Bartko PE, Siller-Matula J, Winter MP, Anvari-Pirsch A, Goliasch G, Hengstenberg C, Mascherbauer J. Volume Status Impacts CMR-Extracellular Volume Measurements and Outcome in AS Undergoing TAVR. JACC Cardiovasc Imaging. 2021 Feb;14(2):516-518. doi: 10.1016/j.jcmg.2020.08.010. Epub 2020 Sep 30. No abstract available. — View Citation

Nitsche C, Kammerlander AA, Koschutnik M, Sinnhuber L, Forutan N, Eidenberger A, Dona C, Schartmueller F, Dannenberg V, Winter MP, Siller-Matula J, Anvari-Pirsch A, Goliasch G, Hengstenberg C, Mascherbauer J. Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Fail. 2021 Apr;8(2):1408-1416. doi: 10.1002/ehf2.13226. Epub 2021 Feb 13. — View Citation

Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989 Feb 10;261(6):884-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Change from baseline to 12 months in quantitative fluid levels 3 and 12 months following TAVR
Other Change from baseline to 12 months in NT-proBNP levels 3 and 12 months following TAVR
Other Change from baseline to 12 months in eGFR values 3 and 12 months following TAVR
Primary Hospitalization for heart failure and/or all-cause death 3 and 12 months following TAVR
Secondary Change from baseline to 12 months in KCCQ scores 3 and 12 months following TAVR
See also
  Status Clinical Trial Phase
Completed NCT05104528 - Non-Invasive Cardiometry and Ultrasound Guided Inferior Vena Cava Collapsibility Index in Assessing Fluid Responsiveness N/A
Completed NCT05070819 - Atrial Natriuretic Peptide in Assessing Fluid Status N/A
Completed NCT04131361 - Inferior Vena Cava Diameter Dependent Colloid Challenge Versus Routine Crystalloid Strategy Transurethral Resection Prostate N/A
Completed NCT04645121 - Carbon Monoxide-based Rebreathing Method and Bioimpedance in Hemodialysis Patients
Completed NCT03505788 - Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR) Phase 4
Active, not recruiting NCT04882358 - Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion N/A
Not yet recruiting NCT06414759 - Efficacy and Safety of Combination Diuretic Therapy in Patients With Acute Decompensated Heart Failure and Volume Overload Phase 4
Active, not recruiting NCT04334668 - Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure N/A
Withdrawn NCT01617798 - Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis N/A
Completed NCT04019314 - Assessment of ProEnkephalin to Detect Acute Kidney Injury (AKI) N/A
Completed NCT03194750 - Ultrasound Assessment of Volume in Patients on Continuous Dialysis N/A
Recruiting NCT05965934 - Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0 Phase 1/Phase 2
Recruiting NCT05240833 - VExUS-guided Fluid Management in Patients With Acute Kidney Injury in the Intensive Care Unit N/A
Completed NCT04623281 - Haemodialysis Outcomes & Patient Empowerment Study 02
Completed NCT03168126 - Advanced Hemodynamic Monitoring in Free Flap Surgery N/A
Recruiting NCT05217342 - PVP-Guided Decongestive Therapy in HF Phase 4
Completed NCT04775576 - Comparison of Conventional Fluid Management Protocol With Targeted Pleth Variability Index (PVI) Monitoring Protocol During Total Abdominal Hysterectomy and Bilateral Salpingooferectomy Operation N/A
Completed NCT05735288 - Haemodialysis Outcomes & Patient Empowerment Study 03
Recruiting NCT05595395 - The Enteral Resuscitation In Intensive Care Pilot- Study N/A
Terminated NCT02769351 - Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration